Humacyte, Inc. (HUMA) stock

HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30

$0.59+0.00 (+0.29%)

Close on Nov 11, 2026Market cap $164.37MP/E –Yield –

Humacyte EPS

Diluted earnings per share is net income divided by the share count including options and convertible securities.

Humacyte's EPS for the twelve months ending Sep 30, 2026 was -$0.44. For fiscal 2025 it was -$0.26. The highest annual figure on record is -$0.12 in fiscal 2022.

Annual eps

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$0.26	–
FY2024	Dec 31, 2024	-$1.26	–
FY2023	Dec 31, 2023	-$1.07	–
FY2022	Dec 31, 2022	-$0.12	–
FY2021	Dec 31, 2021	-$0.66	–
FY2020	Dec 31, 2020	-$11.54	–

Quarterly eps

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	-$0.06	–
Q2 FY2026	Jun 30, 2026	-$0.16	–
Q1 FY2026	Mar 31, 2026	-$0.09	-132.1%
Q4 FY2025	Dec 31, 2025	-$0.13	–
Q3 FY2025	Sep 30, 2025	-$0.11	–
Q2 FY2025	Jun 30, 2025	-$0.24	–
Q1 FY2025	Mar 31, 2025	$0.28	–
Q4 FY2024	Dec 31, 2024	-$0.16	–
Q3 FY2024	Sep 30, 2024	-$0.33	–
Q2 FY2024	Jun 30, 2024	-$0.48	–
Q1 FY2024	Mar 31, 2024	-$0.29	–
Q4 FY2023	Dec 31, 2023	-$0.24	–
Q3 FY2023	Sep 30, 2023	-$0.25	–
Q2 FY2023	Jun 30, 2023	-$0.22	-162.9%
Q1 FY2023	Mar 31, 2023	-$0.36	–
Q4 FY2022	Dec 31, 2022	-$0.04	–
Q3 FY2022	Sep 30, 2022	-$0.25	–
Q2 FY2022	Jun 30, 2022	$0.35	–
Q1 FY2022	Mar 31, 2022	-$0.19	–
Q3 FY2021	Sep 30, 2021	-$0.72	–
Q2 FY2021	Jun 30, 2021	-$2.89	–
Q1 FY2021	Mar 31, 2021	-$3.46	–
Q4 FY2020	Dec 31, 2020	-$2.80	–
Q3 FY2020	Sep 30, 2020	-$3.07	–